EGFR and neoplasm: In this study, 42 tumor samples from 42 patients affected by PM were analyzed using a targeted amplicon-based panel identifying mutations in cancer-related genes such as EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2 and amplifications in EGFR, MET, PIK3CA, FGFR1 and FGFR2.